171 related articles for article (PubMed ID: 1649576)
1. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Rooke R; Parniak MA; Tremblay M; Soudeyns H; Li XG; Gao Q; Yao XJ; Wainberg MA
Antimicrob Agents Chemother; 1991 May; 35(5):988-91. PubMed ID: 1649576
[TBL] [Abstract][Full Text] [Related]
2. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.
Soudeyns H; Yao XI; Gao Q; Belleau B; Kraus JL; Nguyen-Ba N; Spira B; Wainberg MA
Antimicrob Agents Chemother; 1991 Jul; 35(7):1386-90. PubMed ID: 1929298
[TBL] [Abstract][Full Text] [Related]
3. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA
Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634
[TBL] [Abstract][Full Text] [Related]
4. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
5. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
6. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
Eron JJ; Johnson VA; Merrill DP; Chou TC; Hirsch MS
Antimicrob Agents Chemother; 1992 Jul; 36(7):1559-62. PubMed ID: 1324648
[TBL] [Abstract][Full Text] [Related]
9. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
[TBL] [Abstract][Full Text] [Related]
10. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Larder BA; Darby G; Richman DD
Science; 1989 Mar; 243(4899):1731-4. PubMed ID: 2467383
[TBL] [Abstract][Full Text] [Related]
11. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
12. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Geleziunas R; Arts EJ; Boulerice F; Goldman H; Wainberg MA
Antimicrob Agents Chemother; 1993 Jun; 37(6):1305-12. PubMed ID: 8392310
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Palmer S; Harmenberg J; Cox S
Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
Richman DD
Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
[TBL] [Abstract][Full Text] [Related]
18. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA
Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus.
Hamamoto Y; Nakashima H; Matsui T; Matsuda A; Ueda T; Yamamoto N
Antimicrob Agents Chemother; 1987 Jun; 31(6):907-10. PubMed ID: 3039911
[TBL] [Abstract][Full Text] [Related]
20. 3TC/AZT: just another combination.
GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
